GW1929

GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential[1][2].

Product Specifications

CAS Number

[196808-24-9]

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/gw1929.html

Concentration

10mM

Purity

99.93

Solubility

DMSO : ≥ 35 mg/mL

Smiles

O=C(O)[C@H](CC1=CC=C(C=C1)OCCN(C)C2=NC=CC=C2)NC3=CC=CC=C3C(C4=CC=CC=C4)=O

Molecular Formula

C30H29N3O4

Molecular Weight

495.57

References & Citations

[1]Brown KK, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48 (7) :1415-24.|[2]Wojtowicz AK, et al. PPAR-γ agonist GW1929 but not antagonist GW9662 reduces TBBPA-induced neurotoxicity in primary neocortical cells. Neurotox Res. 2014 Apr;25 (3) :311-22.